VFA
TOVX icon

Valeo Financial Advisors’s Theriva Biologics TOVX Stock Holding History

Valeo Financial Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3
Closed -$342 – 1913
2019
Q4 		$0 Hold
3
– – ﹤0.01% 1721
2019
Q3 		$0 Hold
3
– – ﹤0.01% 1670
2019
Q2 		$0 Hold
3
– – ﹤0.01% 1659
2019
Q1 		$1K Hold
3
– – ﹤0.01% 1492
2018
Q4 		$0 Hold
3
– – ﹤0.01% 1718
2018
Q3 		$1K Hold
3
– – ﹤0.01% 1688
2018
Q2 		$3K Hold
3
– – ﹤0.01% 1285
2018
Q1 		$10K Buy
+3
New +$11.4K ﹤0.01% 930

Other funds holding TOVX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Valeo Financial Advisors's TOVX Position: Q1 2020 in Review

Valeo Financial Advisors sold out of Theriva Biologics (TOVX) in Q1 2020, closing a stake of 3 shares — an estimated $342 sold.

Valeo Financial Advisors first reported a position in TOVX in Q1 2018 and held it in 8 quarters. The position peaked at $10K in Q1 2018. 18 funds tracked by Wall St. Rank hold TOVX as of Q1 2020.

  • Valeo Financial Advisors reported no remaining Theriva Biologics position as of Q1 2020 after selling out during the quarter.
  • Valeo Financial Advisors sold 3 Theriva Biologics shares in Q1 2020, an estimated $342.
  • Valeo Financial Advisors first reported a position in Theriva Biologics in Q1 2018 and held it in 8 quarters.
  • Valeo Financial Advisors's Theriva Biologics position peaked at $10K in Q1 2018.
  • 18 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2020.

Based on Valeo Financial Advisors's 13F filing for Q1 2020, filed 13 Apr 2020.